Intravenous Immunoglobulin Market
Number of pages: 100 | Report Format: PDF | Published date: 31 January, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 11 billion |
|
Revenue forecast in 2030 |
US$ 20.56 billion |
|
Growth Rate |
CAGR of 7.2% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments covered |
Application, Form, End-user, and Region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global intravenous immunoglobulin market was valued at US$ 11 billion in 2021 and is expected to witness a CAGR of 7.2% during the forecast period from 2022 to 2030.
Market Fundamentals
Intravenous immunoglobulin (IVIG) is a pool of immunoglobulins, primarily used as therapy for individuals with antibody deficiencies. It is prepared using a collection of immunoglobulins (antibodies) from the plasma of healthy donors. In healthy people, immune systems manufacture immunoglobulins to defend against infections. Even though plasma, a blood component, is used to make intravenous immunoglobulin, there is little chance of contracting a blood-borne infection. The U.S. Food and Drug Administration (FDA) has authorized the administration of intravenous immune globulin (IVIG), for the treatment of immune thrombocytopenic purpura (ITP), primary immunodeficiency, secondary immunodeficiency, pediatric HIV infection, Kawasaki disease, preventing graft versus host disease (GVHD), and infection in bone marrow transplant recipients, among other conditions.
Contrary to many rheumatology-recommended drugs, intravenous immunoglobulin (IVIG) does not raise the risk of infection. Intravenous immunoglobulin functions in various ways to stop the body from attacking itself and lessen inflammatory responses. It is regarded as safe to use while nursing and pregnant. Intravenous immunoglobulin is administered for some rheumatologic conditions, including pediatric Kawasaki's illness. Inflammatory muscle illnesses such juvenile dermatomyositis, polymyositis, and dermatomyositis can also be treated with intravenous immunoglobulin. It can be used to treat systemic lupus erythematosus patients with extremely low platelet counts (idiopathic thrombocytopenic purpura).
Significant research has been undertaken into the mechanism of intravenous immunoglobulin in treating autoimmune and inflammatory diseases. Understanding the major intravenous immunoglobulin mechanisms has allowed for the coherent development of IVIG mimetics and alternatives for several IVIg-treatable conditions.
[9857034]
Market Dynamics
The global intravenous immunoglobulin market is expanding because of a considerable increase in the elderly population and the number of hemophiliac patients. Other growth attributes are the development of innovative technologies for producing immunoglobulin and improved purifying methods (with better plasma yield). Additionally, an increase in the prevalence of disorders, including hypogammaglobulinemia and chronic inflammatory demyelinating polyneuropathy (CIDP) is anticipated to surge the market expansion. It is anticipated that the widespread use of intravenous immunoglobulins in the treatment of numerous diseases will soon open profitable business opportunities. However, the use of intravenous immunoglobulin products is subject to strict government rules, and there is a substantial danger that they will have unfavorable side effects. The high cost of Intravenous immunoglobulin therapy will prevent widespread use, limiting market revenue growth over the projection period.
The global intravenous immunoglobulin market has been analyzed from four perspectives: Application, Form, End-user, and Region.
Intravenous Immunoglobulin Market by Application
Based on applications, the global intravenous immunoglobulin market has been subdivided hypogammaglobulinemia, myasthenia gravis, immunodeficiency diseases, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, inflammatory myopathies, and others. Immunodeficiency diseases currently dominate the global intravenous immunoglobulin market. The rising prevalence of primary and acquired immunodeficiency illnesses is to account for this dominance. To eradicate the infections, PID & AID require intravenous immunoglobulin treatment. The best alternative to intravenous immunoglobulin replacement therapy for the treatment of immune-deficiency illnesses is currently available. Therefore, it is anticipated that the global market will continue to expand in subsequent years. In 2021, the chronic inflammatory demyelinating polyneuropathy (CIDP) segment had the second-largest revenue share. Diabetes mellitus patients typically have it. Steroids, plasmapheresis, and immunosuppressive medications are all used to treat chronic inflammatory demyelinating polyneuropathy (CIDP). Intravenous immunoglobulin is a potent and durable substitute for these approaches. The associated advantages of safety, minimal invasiveness, and ease of administration are fostering the market expansion.
Intravenous immunoglobulin Market by Form
[4234234]
The global intravenous immunoglobulin market is segmented into liquid and lyophilized, based on form. The liquid segment is anticipated to dominate the global intravenous immunoglobulin market. Because of faster infusion times and simpler preparation and administration, the liquid form is more practical for patients and medical professionals. Liquid form is recommended since mixing the powder with either water or saline is a laborious operation that is inconvenient for healthcare workers in emergencies. Because it is simpler to administer, liquid form of intravenous immunoglobulin is a ready-to-use solution that is more convenient for patients and healthcare professionals. Additionally, a shorter infusion period makes it easier to monitor clinical procedures and more tolerable for patients, which supports market growth.
Intravenous immunoglobulin Market by End-user
Based on end-user, the global intravenous immunoglobulin market has been divided into, hospitals & clinics, home care. The hospital pharmacy segment dominates the global intravenous immunoglobulin market. This is a result of the extensive network of hospitals and the practical selection of goods that are readily available from hospital pharmacies. In addition, the rising prevalence of hepatitis C, primary immunological deficiencies, and other illnesses has increased hospital admissions globally, increasing consumer demand for hospital pharmacies. Hospitals also provide quick reimbursement, treatment, and appropriate care to a large number of patients, enabling a rise in the proportion of patients choosing hospital pharmacies.
Intravenous immunoglobulin Market by Region
Based on region, the global intravenous immunoglobulin market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the intravenous immunoglobulin market. The primary drivers of market expansion include expanding clinician propensity for these medicines, rising awareness of items used in the treatment of immunodeficiency illnesses, and rising healthcare spending. Additionally, it is projected that the administration of IVIG therapies with the growing presence of well-established healthcare and research infrastructure and the steadily rising number of product approvals from the U.S. FDA. Some factors influencing this industry's expansion are changing lifestyles and an increase in the number of geriatrics at risk for chronic diseases.
Additionally, it is anticipated that rising PID incidences will offer this market chances for future expansion. Autoimmune disorders are the third most common cause of chronic illnesses in the United States. The National Institutes of Health estimates that between 5% and 8% of the U.S. population will be affected by diseases because many autoimmune conditions are infrequent. For unknown reasons, autoimmune diseases are becoming more prevalent. Over the predicted period, the number is anticipated to increase.
Competitive Landscape
Some of the prominent players operating in the global intravenous immunoglobulin market are:
Strategic Developments
The global intravenous immunoglobulin market is expected to grow at a CAGR of 7.2% in the forecast period.
Biotest AG, Octapharma AG, LFB Biotechnologies, Grifols SA, and Takeda Pharmaceuticals Inc. are a few key players in the global intravenous immunoglobulin market.
The immunodeficiency disease segment dominates the global intravenous immunoglobulin market.
Asia Pacific region is expected to witness the highest global intravenous immunoglobulin market growth in the forecast period.
The global intravenous immunoglobulin market was US$ 11 billion in 2021.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst